Compass Therapeutics, Inc. (CMPX): Total Liabilities
$22.80M
As of 2025-12-31
$24.12M
As of 2026-06-30
+8.2%
3-year compound annual growth
+13.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.80M | +50.3% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $15.17M | +82.0% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $8.34M | -53.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $18.01M | +31.6% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $13.68M | +14.3% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $11.97M | n/a | 2022-03-18, Balance as of period end |
| 2020-03-31 | $111.8K | n/a | 2020-06-08, Balance as of period end |
| 2019-12-31 | $19.11M | n/a | 2021-03-05, Balance as of period end |
| 2019-03-31 | $75.5K | n/a | 2020-06-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $22.80M | +50.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $11.18B | -1.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $1.38B | +22.1% |
Compare CMPX, VXRT, RGEN, CSBR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗